002019.SZ Stock Analysis
00
Avoid
Based on Eyestock quantitative analysis, 002019.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production and sale of pharmaceutical products, active pharmaceutical ingredients and polymer materials. The company is headquartered in Hangzhou, Zhejiang and currently employs 4,285 full-time employees. The company went IPO on 2004-07-13. The firm operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The firm's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The firm distributes its products in domestic and overseas markets.